Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 106 entries
Sorted by: Best Match Show Resources per page
Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L.
PMID: 24381668
Can Urol Assoc J. 2013 Nov-Dec;7(11):450-3. doi: 10.5489/cuaj.262.

INTRODUCTION: This retrospective review compares prostate-specific antigen (PSA) doubling time (DT) prior to the initiation of a 5-alpha-reductase inhibitor (pre-5-ARI) to after the PSA nadir (post-nadir) has been reached for patients on active surveillance for favourable-risk prostate cancer.METHODS: Between...

Cite
Chiang AS, Loblaw DA, Jethava V, et al. Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Can Urol Assoc J. 2013;7(11):450-3doi: 10.5489/cuaj.262.
Chiang, A. S., Loblaw, D. A., Jethava, V., Sethukavalan, P., Zhang, L., Vesprini, D., Mamedov, A., Nam, R., & Klotz, L. (2013). Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 7(11), 450-3. https://doi.org/10.5489/cuaj.262
Chiang, Andrew S, et al. "Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 7,11 (2013): 450-3. doi: https://doi.org/10.5489/cuaj.262
Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L. Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Can Urol Assoc J. 2013 Nov-Dec;7(11):450-3. doi: 10.5489/cuaj.262. PMID: 24381668; PMCID: PMC3876449.
Copy Download .nbib Format: NLM
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.

Reviews in urology

Lepor H.
PMID: 17192797
Rev Urol. 2006;8(4):183-9.

Medical therapy is the preferred first-line approach in the management of lower urinary tract symptoms in men with benign prostatic hyperplasia. The magnitude of the improvement in lower urinary tract symptoms observed in response to combination therapy (alpha-blocker plus...

Cite
Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(4):183-9
Lepor, H. (2006). The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Reviews in urology, 8(4), 183-9.
Lepor, Herbert. "The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia." Reviews in urology vol. 8,4 (2006): 183-9.
Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(4):183-9. PMID: 17192797; PMCID: PMC1751032.
Copy Download .nbib Format: NLM
The medical therapy of prostatic symptoms study: what will we learn?.

Reviews in urology

Slawin KM.
PMID: 16985963
Rev Urol. 2003;5:S42-7.

Until recently, benign prostatic hyperplasia (BPH) was thought of as a relatively uncomplicated disease process resulting from age-related enlargement of the prostate gland, which was thought to cause all of the symptoms associated with the disease. Prostatectomy was considered...

Cite
Slawin KM. The medical therapy of prostatic symptoms study: what will we learn?. Rev Urol. 2003;5:S42-7
Slawin, K. M. (2003). The medical therapy of prostatic symptoms study: what will we learn?. Reviews in urology, 5S42-7.
Slawin, Kevin M. "The medical therapy of prostatic symptoms study: what will we learn?." Reviews in urology vol. 5 (2003): S42-7.
Slawin KM. The medical therapy of prostatic symptoms study: what will we learn?. Rev Urol. 2003;5:S42-7. PMID: 16985963; PMCID: PMC1502351.
Copy Download .nbib Format: NLM
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.

Reviews in urology

Roehrborn CG.
PMID: 16985965
Rev Urol. 2003;5:S12-21.

Lower urinary tract symptoms (LUTS) associated with clinical benign prostatic hyperplasia (BPH) are a common occurrence in aging men, causing bother and interference with daily activities and affecting disease-specific quality of life. There is increasing evidence to suggest that,...

Cite
Roehrborn CG. 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol. 2003;5:S12-21
Roehrborn, C. G. (2003). 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Reviews in urology, 5S12-21.
Roehrborn, Claus G. "5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia." Reviews in urology vol. 5 (2003): S12-21.
Roehrborn CG. 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia. Rev Urol. 2003;5:S12-21. PMID: 16985965; PMCID: PMC1502358.
Copy Download .nbib Format: NLM
Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations.

Prostate international

Choi YS, Bae WJ, Kim SJ, Kim KS, Cho HJ, Hong SH, Lee JY, Hwang TK, Kim SW.
PMID: 24392442
Prostate Int. 2013;1(4):169-76. doi: 10.12954/PI.13030. Epub 2013 Dec 30.

PURPOSE: High-Performance System (HPS) laser photo vaporization of the prostate (PVP) is a widely used procedure nowadays. The safety and efficacy of the procedure has been affirmed in general patients with benign prostatic hyperplasia (BPH), but data on the...

Cite
Choi YS, Bae WJ, Kim SJ, et al. Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. Prostate Int. 2013;1(4):169-76doi: 10.12954/PI.13030.
Choi, Y. S., Bae, W. J., Kim, S. J., Kim, K. S., Cho, H. J., Hong, S. H., Lee, J. Y., Hwang, T. K., & Kim, S. W. (2013). Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. Prostate international, 1(4), 169-76. https://doi.org/10.12954/PI.13030
Choi, Yong Sun, et al. "Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations." Prostate international vol. 1,4 (2013): 169-76. doi: https://doi.org/10.12954/PI.13030
Choi YS, Bae WJ, Kim SJ, Kim KS, Cho HJ, Hong SH, Lee JY, Hwang TK, Kim SW. Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. Prostate Int. 2013;1(4):169-76. doi: 10.12954/PI.13030. Epub 2013 Dec 30. PMID: 24392442; PMCID: PMC3879055.
Copy Download .nbib Format: NLM
[Medical therapy of lower urinary tract symptoms [corrected]].

Der Urologe. Ausg. A

Strittmatter F, Madersbacher S, Stief CG, Gratzke C.
PMID: 22782192
Urologe A. 2012 Aug;51(8):1125-36. doi: 10.1007/s00120-012-2943-1.

Male lower urinary tract symptoms (LUTS) include storage and voiding disorders and should be carefully evaluated before the start of any treatment. Medical therapy is directed at improving symptoms and reducing the risk of progression in order to improve...

Cite
Strittmatter F, Madersbacher S, Stief CG, et al. Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Urologe A. 2012;51(8):1125-36doi: 10.1007/s00120-012-2943-1.
Strittmatter, F., Madersbacher, S., Stief, C. G., & Gratzke, C. (2012). Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Der Urologe. Ausg. A, 51(8), 1125-36. https://doi.org/10.1007/s00120-012-2943-1
Strittmatter, F, et al. "Medikamentöse Therapie des benignen Prostatasyndroms." [Medical therapy of lower urinary tract symptoms [corrected]]. Der Urologe. Ausg. A vol. 51,8 (2012): 1125-36. doi: https://doi.org/10.1007/s00120-012-2943-1
Strittmatter F, Madersbacher S, Stief CG, Gratzke C. Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Urologe A. 2012 Aug;51(8):1125-36. doi: 10.1007/s00120-012-2943-1. German. PMID: 22782192.
Copy Download .nbib Format: NLM
Update on medical therapy for male LUTS.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Radomski SB.
PMID: 25243039
Can Urol Assoc J. 2014 Jul;8(7):S148-50. doi: 10.5489/cuaj.2310.

The medical management of lower urinary tract symptoms (LUTS) is aimed at addressing voiding and storage symptoms in patients with benign prostate hyperplasia (BPH) symptoms with or without an over-active bladder (OAB). Current available options for BPH include alpha-blockers,...

Cite
Radomski SB. Update on medical therapy for male LUTS. Can Urol Assoc J. 2014;8(7):S148-50doi: 10.5489/cuaj.2310.
Radomski, S. B. (2014). Update on medical therapy for male LUTS. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(7), S148-50. https://doi.org/10.5489/cuaj.2310
Radomski, Sidney B. "Update on medical therapy for male LUTS." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 8,7 (2014): S148-50. doi: https://doi.org/10.5489/cuaj.2310
Radomski SB. Update on medical therapy for male LUTS. Can Urol Assoc J. 2014 Jul;8(7):S148-50. doi: 10.5489/cuaj.2310. PMID: 25243039; PMCID: PMC4145697.
Copy Download .nbib Format: NLM
Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis.

Urology

Wu Y, Wang Y, Gu Y, Xia J, Qian Q, Hong Y.
PMID: 32745485
Urology. 2020 Nov;145:216-223. doi: 10.1016/j.urology.2020.05.105. Epub 2020 Jul 31.

We systematically assessed the effect of 5-alpha-reductase inhibitors (5-ARIs) and/or alpha-blockers use on prostate cancer (CaP) incidence and outcomes, including CaP pathologic progression, CaP-specific mortality, and all-cause mortality. 5-ARIs but not alpha-blockers decreased risk of overall CaP, low grade...

Cite
Wu Y, Wang Y, Gu Y, et al. Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis. Urology. 2020;145:216-223doi: 10.1016/j.urology.2020.05.105.
Wu, Y., Wang, Y., Gu, Y., Xia, J., Qian, Q., & Hong, Y. (2020). Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis. Urology, 145216-223. https://doi.org/10.1016/j.urology.2020.05.105
Wu, Yougen, et al. "Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis." Urology vol. 145 (2020): 216-223. doi: https://doi.org/10.1016/j.urology.2020.05.105
Wu Y, Wang Y, Gu Y, Xia J, Qian Q, Hong Y. Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis. Urology. 2020 Nov;145:216-223. doi: 10.1016/j.urology.2020.05.105. Epub 2020 Jul 31. PMID: 32745485.
Copy Download .nbib Format: NLM
The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

Clinical epidemiology

Ayodele O, Cabral HJ, McManus D, Jick S.
PMID: 34377032
Clin Epidemiol. 2021 Aug 03;13:661-673. doi: 10.2147/CLEP.S317019. eCollection 2021.

BACKGROUND: Many men receive 5-alpha reductase inhibitors (5ARIs) for ongoing treatment of benign prostatic hyperplasia (BPH). The increased risk of cardiovascular complications with 5ARIs has been documented in BPH studies and the occurrence of cerebral venous thrombosis, presumably due...

Cite
Ayodele O, Cabral HJ, McManus D, et al. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs). Clin Epidemiol. 2021;13:661-673doi: 10.2147/CLEP.S317019.
Ayodele, O., Cabral, H. J., McManus, D., & Jick, S. (2021). The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs). Clinical epidemiology, 13661-673. https://doi.org/10.2147/CLEP.S317019
Ayodele, Olulade, et al. "The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs)." Clinical epidemiology vol. 13 (2021): 661-673. doi: https://doi.org/10.2147/CLEP.S317019
Ayodele O, Cabral HJ, McManus D, Jick S. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs). Clin Epidemiol. 2021 Aug 03;13:661-673. doi: 10.2147/CLEP.S317019. eCollection 2021. PMID: 34377032; PMCID: PMC8349190.
Copy Download .nbib Format: NLM
Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin.

The International journal of risk & safety in medicine

Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJG, Irwig MS, Jannini EA, Janssen PKC, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DEJ, Lüning C, Mangin D, Melcangi RC, Rodríguez OWMAAS, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Vašečková B, Waraich A.
PMID: 34719438
Int J Risk Saf Med. 2021 Oct 26; doi: 10.3233/JRS-210023. Epub 2021 Oct 26.

BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin.OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital...

Cite
Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021;doi: 10.3233/JRS-210023.
Healy, D., Bahrick, A., Bak, M., Barbato, A., Calabrò, R. S., Chubak, B. M., Cosci, F., Csoka, A. B., D'Avanzo, B., Diviccaro, S., Giatti, S., Goldstein, I., Graf, H., Hellstrom, W. J. G., Irwig, M. S., Jannini, E. A., Janssen, P. K. C., Khera, M., Kumar, M. T., Le Noury, J., Lew-Starowicz, M., Linden, D. E. J., Lüning, C., Mangin, D., Melcangi, R. C., Rodríguez, O. W. M. A. A. S., Panicker, J. N., Patacchini, A., Pearlman, A. M., Pukall, C. F., Raj, S., Reisman, Y., Rubin, R. S., Schreiber, R., Shipko, S., Vašečková, B., & Waraich, A. (2021). Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. The International journal of risk & safety in medicine, . https://doi.org/10.3233/JRS-210023
Healy, David, et al. "Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin." The International journal of risk & safety in medicine vol. (2021). doi: https://doi.org/10.3233/JRS-210023
Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJG, Irwig MS, Jannini EA, Janssen PKC, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DEJ, Lüning C, Mangin D, Melcangi RC, Rodríguez OWMAAS, Panicker JN, Patacchini A, Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Vašečková B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021 Oct 26; doi: 10.3233/JRS-210023. Epub 2021 Oct 26. PMID: 34719438.
Copy Download .nbib Format: NLM
Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone.

Singapore medical journal

Hatanaka T, Lulic Z, Mefo T, Booth C, Harrison E, Ong G.
PMID: 34157805
Singapore Med J. 2021 Jun 22; doi: 10.11622/smedj.2021080. Epub 2021 Jun 22.

No abstract available.

Cite
Hatanaka T, Lulic Z, Mefo T, et al. Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone. Singapore Med J. 2021;doi: 10.11622/smedj.2021080.
Hatanaka, T., Lulic, Z., Mefo, T., Booth, C., Harrison, E., & Ong, G. (2021). Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone. Singapore medical journal, . https://doi.org/10.11622/smedj.2021080
Hatanaka, Toshiki, et al. "Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone." Singapore medical journal vol. (2021). doi: https://doi.org/10.11622/smedj.2021080
Hatanaka T, Lulic Z, Mefo T, Booth C, Harrison E, Ong G. Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors - dutasteride and finasteride - in the presence of testosterone. Singapore Med J. 2021 Jun 22; doi: 10.11622/smedj.2021080. Epub 2021 Jun 22. PMID: 34157805.
Copy Download .nbib Format: NLM
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).

Cureus

Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A.
PMID: 33643746
Cureus. 2021 Feb 01;13(2):e13047. doi: 10.7759/cureus.13047.

Background and objective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and subsequent infectivity are mediated by androgens and the androgen receptors through the regulation of transmembrane protease, serine 2 (TMPRSS2). Androgenetic alopecia (AGA) predisposes males to severe...

Cite
Cadegiani FA, McCoy J, Gustavo Wambier C, et al. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021;13(2):e13047doi: 10.7759/cureus.13047.
Cadegiani, F. A., McCoy, J., Gustavo Wambier, C., & Goren, A. (2021). Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus, 13(2), e13047. https://doi.org/10.7759/cureus.13047
Cadegiani, Flavio A, et al. "Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical)." Cureus vol. 13,2 (2021): e13047. doi: https://doi.org/10.7759/cureus.13047
Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021 Feb 01;13(2):e13047. doi: 10.7759/cureus.13047. PMID: 33643746; PMCID: PMC7885746.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 106 entries